Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,222 | -5,072 | -41,662 | -31,063 | -20,600 |
| Depreciation Amortization | 372 | 184 | 409 | 270 | 189 |
| Accounts payable and accrued liabilities | -2,526 | -3,008 | 84 | -2,088 | -2,747 |
| Other Working Capital | -6,419 | -6,518 | -1,071 | 2,558 | -1,610 |
| Other Operating Activity | 3,801 | 3,490 | 2,615 | 4,207 | 4,166 |
| Operating Cash Flow | $-22,994 | $-10,924 | $-39,625 | $-26,116 | $-20,602 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 49,684 | 24,752 | -80,720 | -90,421 | -17,825 |
| PPE Investments | -168 | -81 | -2,436 | -22 | N/A |
| Investing Cash Flow | $49,516 | $24,671 | $-83,156 | $-90,443 | $-17,825 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 10,610 | 1,584 | 70,835 | 70,697 | 51 |
| Other Financing Activity | -79 | -16 | -1,312 | -996 | -247 |
| Financing Cash Flow | $10,531 | $1,568 | $69,523 | $69,701 | $-196 |
| Beginning Cash Position | 34,080 | 34,080 | 87,338 | 87,338 | 87,338 |
| End Cash Position | 71,133 | 49,395 | 34,080 | 40,480 | 48,715 |
| Net Cash Flow | $37,053 | $15,315 | $-53,258 | $-46,858 | $-38,623 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,994 | -10,924 | -39,625 | -26,116 | -20,602 |
| Capital Expenditure | -168 | -81 | -2,436 | -22 | N/A |
| Free Cash Flow | -23,162 | -11,005 | -42,061 | -26,138 | -20,602 |